Revenue Growth Drivers

Recurring infusion-product demand can support baseline revenue durability, but the absence of disclosed 5-year CAGR data limits evidence of sustained compounding versus larger peers.

Low capex intensity at 2.5% of revenue suggests modest reinvestment needs, which can preserve cash for growth initiatives, though it does not prove faster scaling than peers.

R&D spending near 9.9% of revenue indicates ongoing product support and incremental innovation capacity, but current returns have not yet translated into stronger growth than peers.

The company’s revenue base appears capable of incremental expansion, yet negative TTM ROIC of -7.7% implies growth has not been converting into efficient value creation versus peers.

Market Tailwinds

Specialty plasma-derived and infusion-related products can benefit from recurring clinical demand, but this is a narrower tailwind than the broader addressable markets served by larger peers.

The business likely benefits from replacement and maintenance demand rather than one-time sales, which supports durability, though it usually caps growth below faster-expanding peer platforms.

Limited disclosed concentration metrics prevent evidence of broad customer diversification, so market tailwinds appear real but not strong enough to indicate superior multi-year expansion versus peers.

Compared with diversified medtech peers, KRMD’s end-market support looks steadier than cyclical industrial demand, but less expansive than platforms with larger adjacent-market optionality.

Scalability Expansion

Capex at 2.5% of revenue suggests a relatively asset-light model, but the company’s weak profitability indicates scaling has not yet produced strong operating leverage versus peers.

Cash conversion cycle of 83 days signals working-capital drag, which can slow reinvestment speed and reduce the pace of revenue compounding relative to more efficient peers.

Net debt to EBITDA of 5.0x materially constrains expansion capacity, because leverage reduces flexibility for acquisitions, inventory build, and commercial investment versus stronger peers.

Interest coverage of zero indicates limited financial headroom, which can restrict scaling initiatives and makes long-term expansion less resilient than better-capitalized peer platforms.

Constraints Limitations

Negative TTM ROIC of -7.7% shows current growth is not earning adequate returns, which structurally weakens compounding capacity versus profitable peers.

Net debt to EBITDA near 5.0x materially limits strategic flexibility, because debt service competes with reinvestment and reduces room for sustained expansion.

Interest coverage of zero signals severe earnings pressure, which can constrain funding for sales, product, and distribution growth more than in healthier peer companies.

The lack of disclosed historical CAGR data and weak current economics make it difficult to evidence durable multi-year scaling, keeping long-term growth visibility below peers.

Overall Score

KRMD shows a durable but constrained growth profile: recurring demand and modest reinvestment needs support baseline expansion, while leverage and weak returns limit compounding versus peers.

Score Driver: Leverage Constrained Expansion